This article is more than 5 years old. Information may no longer be current.

Phase 2 study: Squalamine did not raise blood pressure

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PLYMOUTH MEETING, Pa. — Squalamine, a drug in development as a systemic treatment for exudative age-related macular degeneration, does not appear to have an effect on blood pressure, according to a press release from Genaera Corp., the drug's developer.

Endothelial nitric oxide synthase inhibition is a side effect of drugs that inhibit vascular endothelial growth factor (VEGF), and it may contribute to hypertension and cardiovascular events seen in patients receiving such drugs, according to the press release.

At a meeting of the Angiogenesis Foundation in Boston, Andrew V. Albright, PhD, of Genaera Corp. presented results of in vitro testing showing that the company's drug Evizon (squalamine) does not inhibit endothelial nitric oxide synthase. He also presented safety data from a phase 2 study of the drug, showing that 124 patients treated with the drug for exudative AMD showed no significant increases in systolic or diastolic blood pressures, according to the release.